Table 1

Recipient, donor, and graft characteristics

Recipient characteristicsObservations (n)Median (minimum–maximum) or N (%)
Gender (% male)4819 (39.6)
Age (years)4848.4 (26.2–65.5)
Weight (kg)4868.8 (48.0–111.1)
BMI (kg/m2)4825.1 (18.9–29.8)
Duration of diabetes (years)4828.5 (11–57)
HbA1c (%)487.2 (5.7–9.2)
HbA1c (mmol/mol)4855 (39–77)
Insulin requirement*48
 Units/day32.6 (11.4–62.1)
 Units/kg/day0.5 (0.2–0.8)
Autoantibodies45
 Anti-insulin (% positive)44 (97.8)
 Anti-GAD65 (% positive)29 (64.4)
 Anti-ICA512 (% positive)20 (44.4)
Clarke score486 (3–7)
HYPO score481,253.5 (58–8,467)
SHE 1 year pretx (N)486.5 (0–336)
Glycemic LI48622 (100–1,500)
GFR (mL/min/1.73 m2)48102 (80–130)
Diab Microvasc Complic48
 Nonproliferative retinopathy (%)16 (33.3)
 Proliferative retinopathy (%)6 (16.7)
 Microalbuminuria (%)5 (10.4)
Donor/pancreas characteristics
Donor age (years)7542.8 (18.6–60.7)
Donor BMI (kg/m2)7533.4 (20.9–50.3)
Donor sex (% male)7553 (70.7)
Pancreas cold ischemia time (h/per isolation)757.7 (3.7–13.0)
PHPI lot characteristics§
 Total IEQ transplanted (per lot)75480,500 (282,156–1,005,822)
 Tissue volume (mL/lot)754.0 (0.8–11.5)
Total dose/subject
 Total IEQ transplanted (per subject)48820,286 (286,565–1,562,425)
 Total IEQ/kg transplanted (per subject)4811,972 (5,227–25,553)
  • Diab. Microvasc. Complic, diabetic microvascular complications; pretx, pretransplant.

  • *Subject’s report of 7 days of insulin usage data nearest to the date of transplant.

  • †Baseline autoantibody samples were not collected from three subjects.

  • ‡See full definitions in Appendix 3 in the Supplementary Data.

  • §One donor pancreas produced one lot of PHPI, which was one dose administered.